Instil Bio, Inc. engaged RSM US LLP as its auditor.
“(the “Company”) approved the appointment of RSM US LLP (“RSM”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Instil Bio, Inc. — fact timeline
Source-grounded facts extracted from Instil Bio, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Instil Bio, Inc. dismissed Deloitte & Touche LLP as its auditor.
“(the “Company”) approved the appointment of RSM US LLP (“RSM”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Instil Bio, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss per share, basic and diluted was $1.21 and $10.70 for the fourth quarter and full year ended December 31, 2025,, EPS Net loss per share, basic and diluted was $1.21 and $10.70 for the fourth quarter and full year ended December 31, 2025,.
“On March 27, 2026, Instil Bio, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the fourth quarter and full year ended December 31, 2025”
Instil Bio, Inc. terminated License and Collaboration Agreement with ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (effective 2026-01-05).
“Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil Bio, Inc., and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (“ImmuneOnco”) entered into an agreement terminating, effective January 5, 2026, the License and Collaboration Agreement dated August 1, 2024 between ImmuneOnco and Axion”
Instil Bio, Inc. reported the quarter ended March 31, 2024 results: EPS Net loss per share, basic and diluted were $3.74.
“On May 10, 2024 , Instil Bio, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended March 31, 2024 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.”
Instil Bio, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
“Instil Bio, Inc. (the “Company”) provided a corporate update and announced its financial results for the fourth quarter and full year ended December 31, 2023 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.